Disruption of SUMO-Specific Protease 2 Induces Mitochondria Mediated Neurodegeneration

PLoS Genetics

Volumn 10, Issue 10, 2014, Pages

  Fu, Jiang ^a   Yu, H M Ivy ^a   Chiu, Shang Yi ^a,c   Mirando, Anthony J ^a   Maruyama, Eri O ^a   Cheng, Jr Gang ^b   Hsu, Wei ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DRP1 PROTEIN; ISOENZYME; SMALL UBIQUITIN RELATED MODIFIER SPECIFIC PROTEASE 2; SUMO PROTEIN; UNCLASSIFIED DRUG; CYSTEINE PROTEINASE; DNM1L PROTEIN, MOUSE; DYNAMIN; SENP2 PROTEIN, MOUSE; SUMO 1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SPECIFICITY; MITOCHONDRIAL DYNAMICS; MOUSE; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARALYSIS; PROTEIN DEPLETION; REGULATORY MECHANISM; SUMOYLATION; ANIMAL; DEGENERATIVE DISEASE; FEMALE; GENETICS; MALE; METABOLISM; MITOCHONDRION; NERVE CELL; PATHOLOGY; PHYSIOLOGY; PROTEIN STABILITY; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; CYSTEINE ENDOPEPTIDASES; DYNAMINS; FEMALE; MALE; MICE, TRANSGENIC; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; NEURONS; PARALYSIS; PROTEIN STABILITY; SUMO-1 PROTEIN; SUMOYLATION;

EID: 84908343054     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004579     Document Type: Article

References (50)

1. Martin S, Nishimune A, Mellor JR, Henley JM, (2007) SUMOylation regulates kainate-receptor-mediated synaptic transmission. Nature 447: 321–325.
2. Shalizi A, Gaudilliere B, Yuan Z, Stegmuller J, Shirogane T, et al. (2006) A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 311: 1012–1017.
3. Flavell SW, Cowan CW, Kim TK, Greer PL, Lin Y, et al. (2006) Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number. Science 311: 1008–1012.
4. Krumova P, Weishaupt JH, (2013) Sumoylation in neurodegenerative diseases. Cell Mol Life Sci 70: 2123–2138.
5. Lieberman AP, (2004) SUMO, a ubiquitin-like modifier implicated in neurodegeneration. Exp Neurol 185: 204–207.
6. Martin S, Wilkinson KA, Nishimune A, Henley JM, (2007) Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction. Nat Rev Neurosci 8: 948–959.
7. Seeler JS, Dejean A, (2003) Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol 4: 690–699.
8. Ouyang J, Valin A, Gill G, (2009) Regulation of transcription factor activity by SUMO modification. Methods Mol Biol 497: 141–152.
9. Geoffroy MC, Hay RT, (2009) An additional role for SUMO in ubiquitin-mediated proteolysis. Nat Rev Mol Cell Biol 10: 564–568.
10. Cubenas-Potts C, Matunis MJ, (2013) SUMO: a multifaceted modifier of chromatin structure and function. Dev Cell 24: 1–12.
11. Ulrich HD, (2009) The SUMO system: an overview. Methods Mol Biol 497: 3–16.
12. Melchior F, (2000) SUMO–nonclassical ubiquitin. Annu Rev Cell Dev Biol 16: 591–626.
13. Gareau JR, Lima CD, (2010) The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 11: 861–871.
14. Melchior F, Schergaut M, Pichler A, (2003) SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem Sci 28: 612–618.
15. Hickey CM, Wilson NR, Hochstrasser M, (2012) Function and regulation of SUMO proteases. Nat Rev Mol Cell Biol 13: 755–766.
16. Jiang M, Chiu SY, Hsu W, (2011) SUMO-specific protease 2 in Mdm2-mediated regulation of p53. Cell Death Differ 18: 1005–1015.
17. Chiu SY, Asai N, Costantini F, Hsu W, (2008) SUMO-Specific Protease 2 Is Essential for Modulating p53-Mdm2 in Development of Trophoblast Stem Cell Niches and Lineages. PLoS Biol 6: e310.
18. Kang X, Qi Y, Zuo Y, Wang Q, Zou Y, et al. (2010) SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. Mol Cell 38: 191–201.
19. Shinbo Y, Niki T, Taira T, Ooe H, Takahashi-Niki K, et al. (2006) Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death Differ 13: 96–108.
20. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, et al. (2004) SUMO modification of Huntingtin and Huntington's disease pathology. Science 304: 100–104.
21. Pountney DL, Huang Y, Burns RJ, Haan E, Thompson PD, et al. (2003) SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Exp Neurol 184: 436–446.
22. Riley BE, Zoghbi HY, Orr HT, (2005) SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal. J Biol Chem 280: 21942–21948.
23. Hattori N, Mizuno Y, (2004) Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet 364: 722–724.
24. Ren D, Tu HC, Kim H, Wang GX, Bean GR, et al. (2010) BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 330: 1390–1393.
25. Wasiak S, Zunino R, McBride HM, (2007) Bax/Bak promote sumoylation of DRP1 and its stable association with mitochondria during apoptotic cell death. J Cell Biol 177: 439–450.
26. Cho DH, Nakamura T, Fang J, Cieplak P, Godzik A, et al. (2009) S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 324: 102–105.
27. Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, et al. (2010) Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol Genet 19: 3919–3935.
28. Pitts KR, Yoon Y, Krueger EW, McNiven MA, (1999) The dynamin-like protein DLP1 is essential for normal distribution and morphology of the endoplasmic reticulum and mitochondria in mammalian cells. Mol Biol Cell 10: 4403–4417.
29. Krumova P, Meulmeester E, Garrido M, Tirard M, Hsiao HH, et al. (2011) Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol 194: 49–60.
30. Li Y, Wang H, Wang S, Quon D, Liu YW, et al. (2003) Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc Natl Acad Sci U S A 100: 259–264.
31. Bender T, Martinou JC, (2013) Where killers meet–permeabilization of the outer mitochondrial membrane during apoptosis. Cold Spring Harb Perspect Biol 5: a011106.
32. Mali P, Esvelt KM, Church GM, (2013) Cas9 as a versatile tool for engineering biology. Nat Methods 10: 957–963.
33. Reddy PH, Reddy TP, Manczak M, Calkins MJ, Shirendeb U, et al. (2011) Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res Rev 67: 103–118.
34. Chan DC, (2012) Fusion and fission: interlinked processes critical for mitochondrial health. Annu Rev Genet 46: 265–287.
35. Harder Z, Zunino R, McBride H, (2004) Sumo1 conjugates mitochondrial substrates and participates in mitochondrial fission. Curr Biol 14: 340–345.
36. Zunino R, Schauss A, Rippstein P, Andrade-Navarro M, McBride HM, (2007) The SUMO protease SENP5 is required to maintain mitochondrial morphology and function. J Cell Sci 120: 1178–1188.
37. Zunino R, Braschi E, Xu L, McBride HM, (2009) Translocation of SenP5 from the nucleoli to the mitochondria modulates DRP1-dependent fission during mitosis. J Biol Chem 284: 17783–17795.
38. Fu J, Jiang M, Mirando AJ, Yu HM, Hsu W, (2009) Reciprocal regulation of Wnt and Gpr177/mouse Wntless is required for embryonic axis formation. Proc Natl Acad Sci U S A 106: 18598–18603.
39. Yu HM, Jin Y, Fu J, Hsu W, (2010) Expression of Gpr177, a Wnt trafficking regulator, in mouse embryogenesis. Dev Dyn 239: 2102–2109.
40. Yu HM, Liu B, Chiu SY, Costantini F, Hsu W, (2005) Development of a unique system for spatiotemporal and lineage-specific gene expression in mice. Proc Natl Acad Sci U S A 102: 8615–8620.
41. Fu J, Ivy Yu HM, Maruyama T, Mirando AJ, Hsu W, (2011) Gpr177/mouse Wntless is essential for Wnt-mediated craniofacial and brain development. Dev Dyn 240: 365–371.
42. Yu HM, Jerchow B, Sheu TJ, Liu B, Costantini F, et al. (2005) The role of Axin2 in calvarial morphogenesis and craniosynostosis. Development 132: 1995–2005.
43. Fu J, Hsu W, (2013) Epidermal Wnt controls hair follicle induction by orchestrating dynamic signaling crosstalk between the epidermis and dermis. J Invest Dermatol 133: 890–898.
44. Maruyama T, Jiang M, Hsu W, (2013) Gpr177, a novel locus for bone mineral density and osteoporosis, regulates osteogenesis and chondrogenesis in skeletal development. J Bone Miner Res 28: 1150–1159.
45. Maruyama T, Mirando AJ, Deng CX, Hsu W, (2010) The balance of WNT and FGF signaling influences mesenchymal stem cell fate during skeletal development. Sci Signal 3: ra40.
46. Yu HM, Liu B, Costantini F, Hsu W, (2007) Impaired neural development caused by inducible expression of Axin in transgenic mice. Mech Dev 124: 146–156.
47. Liu B, Yu HM, Hsu W, (2007) Craniosynostosis caused by Axin2 deficiency is mediated through distinct functions of beta-catenin in proliferation and differentiation. Dev Biol 301: 298–308.
48. Liu B, Yu HM, Huang J, Hsu W, (2008) Co-opted JNK/SAPK signaling in Wnt/beta-catenin-induced tumorigenesis. Neoplasia 10: 1004–1013.
49. Mirando AJ, Maruyama T, Fu J, Yu HM, Hsu W, (2010) Beta-catenin/cyclin D1 mediated development of suture mesenchyme in calvarial morphogenesis. BMC Dev Biol 10: 116.
50. Maruyama EO, Yu HM, Jiang M, Fu J, Hsu W, (2013) Gpr177 deficiency impairs mammary development and prohibits Wnt-induced tumorigenesis. PLoS One 8: e56644.